Floatz logo

Onapristone

Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy

Arno TherapeuticsSmall moleculePhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Jennifer Lee Caswell-Jin
Phase 2BB
Letrozole
Ruth O'Regan
Phase 2BB
Cyclophosphamide
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
Thiotepa
Fred Hutchinson Cancer Center
Phase 2B

View all 37 →

Same molecule, other indications

Onapristone is also rated in:

endometrial endometrioid adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian granulosa cell tumorDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →